Blood biomarkers for Alzheimer’s disease in clinical practice and trials.

2023

https://pubmed.ncbi.nlm.nih.gov/37202517/

Hansson O, Blennow K, Zetterberg H, Dage J.

Nat Aging. 2023 May;3(5):506-519. doi: 10.1038/s43587-023-00403-3

2024 Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study
2024 Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity
2024 Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease
2024 A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
2024 Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns
2024 Acceptable performance of blood biomarker tests of amyloid pathology – recommendations from the Global CEO Initiative on Alzheimer’s Disease
2024 Revised criteria for the diagnosis and staging of Alzheimer’s disease
2024 Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup
2024 Associations of modifiable and non-modifiable risk factors with cognitive functions – a prospective, population-based, 17 years follow-up study of 3,229 individuals
2024 Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers
2024 In vivo detection of Alzheimer’s and Lewy body disease concurrence: Clinical implications and future perspectives
2024 Structural and functional connectivity associations with anterior cingulate sulcal variability
2024 Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study
2024 MRI-Derived AD Signature of Cortical Thinning and Plasma P-Tau217 for Predicting Alzheimer Dementia Among Community-Dwelling Older Adults
2024 Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology